Graft Versus Host Disease Pipeline, Clinical Trials, and Key Companies|Biocon, Medac GmbH, MaaT Pharma, , Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience

Graft Versus Host Disease Pipeline, Clinical Trials, and Key Companies|Biocon, Medac GmbH, MaaT Pharma, , Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience

June 09
14:00 2023
Graft Versus Host Disease Pipeline, Clinical Trials, and Key Companies|Biocon, Medac GmbH, MaaT Pharma, , Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience
DelveInsight Business Research LLP
DelveInsight’s “Graft versus host disease (GVHD) Pipeline Insight, 2023” report provides comprehensive insights about 60+ GvHD companies and 60+ pipeline drugs in the Graft versus host disease pipeline landscape.

(United States, Nevada, Las Vegas), DelveInsight’s “Graft versus host disease (GVHD) Pipeline Insight, 2023” report provides comprehensive insights about 60+ GvHD companies and 60+ pipeline drugs in the Graft versus host disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Graft Versus Host Disease Pipeline Report

  • Over 60+ companies and 60+ pipeline drugs in Graft Versus Host Disease are in various stages of development, and their anticipated acceptance in the Graft Versus Host Disease market would significantly increase market revenue. 

  • Leading Graft Versus Host Disease companies developing novel drug candidates to improve the Graft Versus Host Disease treatment landscape include Biocon, Medac GmbH, Maat Pharma, ElsaLys Biotech, GliaSyndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio, Chia Tai Tianqing Pharmaceutical Group, Amgen, Pfizer, Plexxikon, Medsenic, Xenothera, and others.

  • Promising Graft Versus Host Disease pipeline therapies in various stages of development include Teplizumab, ASC930, and others.

 Graft Versus Host Disease Overview

Graft-versus-host disease is a systemic disorder that occurs when the graft’s immune cells recognize the host as foreign and attack the recipient’s body cells. “Graft” refers to transplanted, or donated tissue, and “host” refers to the tissues of the recipient. It is a common complication after allogeneic hematopoietic stem cell transplant. Cells of the immune system are trained early to differentiate between “self” cells and “non-self” cells. The ability to recognize “non-self” cells depends on a set of genes known as the histocompatibility genes that provide instructions for making a group of related proteins known as major histocompatibility complex (MHC proteins) or human leukocyte antigens.

Graft Versus Host Disease Pipeline Analysis: Drug Profile

Teplizumab: Prevention Bio

MaaT013 is a full-ecosystem, off-the-shelf, standardized, pooled-donor, Microbiome Ecosystem Therapy. It is characterized by a consistently high diversity and richness of microbial species and the presence of ButycoreTM (a group of bacterial species known to produce anti-inflammatory metabolites). MaaT013 aims to restore the symbiotic relationship between the patient’s functional gut microbiome and their immune system to correct the responsiveness and tolerance of immune functions and thus reduce steroid-resistant, gastrointestinal-predominant aGvHD. MaaT013 has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Discover more about the emerging Graft Versus Host Disease drugs @ Graft Versus Host Disease Treatment Drugs

Graft Versus Host Disease Pipeline Therapies and Key Companies

  • Teplizumab: Prevention Bio

  • ASC930: ASC Therapeutics

And many others 

Graft Versus Host Disease Pipeline Therapeutics Assessment

Phases

DelveInsight’s Graft versus host disease pipeline report covers around 60+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

GVHD pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Graft versus host disease products have been categorized under various ROAs such as

  • Oral

  • Intravenous

  • Subcutaneous

Molecule Type

Graft versus host disease Products have been categorized under various Molecule types such as

  • Small molecule

  • Cell Therapy

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.

Scope of the Graft Versus Host Disease Pipeline Report 

  • Coverage: Global 

  • Key Graft Versus Host Disease Companies: Biocon, Medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio, Chia Tai Tianqing Pharmaceutical Group, Amgen, Pfizer, Plexxikon, Medsenic, Xenothera and many others.

  • Key Graft Versus Host Disease Pipeline Therapies: Teplizumab, ASC930, and many others

Find out more about the Graft Versus Host Disease treatment options in development@ Graft Versus Host Disease Clinical Trials

Table of Contents

1. Graft Versus Host Disease Introduction

2. Graft Versus Host Disease Executive Summary

3. Graft Versus Host Disease Overview

4. Graft Versus Host Disease Pipeline Therapeutics

5. Graft Versus Host Disease Late-Stage Products (Phase III)

6. Graft Versus Host Disease Mid-Stage Products (Phase  II)

7. Graft Versus Host Disease Early Stage Products (Phase  I/II)

8. Graft Versus Host Disease Preclinical Stage Products

9. Graft Versus Host Disease Discovery Stage Products

10. Graft Versus Host DiseaseTherapeutic Assessment

11. Graft Versus Host Disease Inactive Products

12. Graft Versus Host Disease Collaborations Assessment- Licensing / Partnering / Funding

13. Graft Versus Host Disease Unmet Needs

14. Graft Versus Host Disease Market Drivers and Barriers

15. Appendix

16. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Categories